COLO B Coloplast A/S Class B

Coloplast A/S - Transactions in connection with share buy-back programme, week 23

Coloplast A/S - Transactions in connection with share buy-back programme, week 23

As mentioned in Announcement no. 02/2020 Coloplast is initiating a share buyback programme totalling up to DKK 500 million.

The programme will commence on 24 February 2020 and is expected to end by 24 August 2020.

The share buyback programme is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations with the purpose of meeting obligations arising from share options programmes or other allocation of shares to employees or to complete a share capital decrease as set out in Articles 5(2)(a) and 5(2)(c) in MAR.

The following transactions have been executed during the period 2 – 4 June 2020:

DateNumber of sharesAverage purchase price, DKKTransaction value, DKK
2 June 20203001,087.49326,247
3 June 20206431,062.41683,130
4 June 20207,4061,052.627,795,704
Accumulated until now under the programme443,352982.59435,631,905

Henceforth, Coloplast owns 3,322,692 treasury B shares of DKK 1 equal to 1.54% of the company’s total share capital.

An overview showing the transaction data for the period 2 – 4 June 2020 is enclosed.

Kind regards,

Investor Relations

Coloplast A/S

Tel.

 

For further information, please contact

  

Investors and analysts

Ellen Bjurgert

Vice President, Investor Relations

Tel. /

Email:

Rasmus Sørensen

Sr. Manager, Investor Relations

Tel. /

Email:

                                                                                       

Press and the media

Lina Danstrup

Sr. Media Relations Manager

Tel. 4911 2607

Email:

Address

Coloplast A/S

Holtedam 1

DK-3050 Humlebaek

Danmark

CVR NR. 69749917

Website

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,000 employees.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2020-06.

All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Attachments

EN
08/06/2020

Underlying

COLO BColoplast A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
COLO B COLOPLAST A/S CLASS B
09/03/25 September 3, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
COLO B COLOPLAST A/S CLASS B
09/02/25 September 2, 2025 1 EN
 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast A/S - Coloplast lancerer ny 5-årig strategi ’Impact4’

Coloplast A/S - Coloplast lancerer ny 5-årig strategi ’Impact4’ Den nye 5-årige strategi, Impact4, vil blive lanceret i dag på selskabets Capital Markets Day 2025. Strategien Impact4 sætter kunden i centrum og udstikker samtidig et ambitiøst mål for selskabet – at hjælpe 4 millioner mennesker på lang sigt. Med Impact4 fokuserer vi på fire strategiske prioriteter, der er afgørende for vores succes og værdiskabelse: ’Grow through innovative customer offerings’ ved at sætte standarden for sundhedspleje og ved at skabe et stærkt fokus på kunderne på tværs af alle vores forretningsområder.’Unl...

September 2, 2025 1 EN
 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast A/S - Coloplast presents new 5-year strategy, Impact4

Coloplast A/S - Coloplast presents new 5-year strategy, Impact4 The new 5-year strategy, Impact4, will be presented today at the company’s Capital Markets Day 2025 The Impact4 strategy puts customers at the centre of everything we do and sets an ambitious goal for the company – to help 4 million people in the long-term. With Impact4, we focus on four strategic priorities which are essential to our success and value creation: Grow through innovative customer offerings, by setting the standard of care and driving strong customer centricity across all our business areas.Unlock next level e...

September 2, 2025 1 EN
 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast A/S - Announcement no. 07/2025 - Coloplast fremlægger nye fi...

Coloplast A/S - Announcement no. 07/2025 - Coloplast fremlægger nye finansielle forventninger frem mod 2030 I forbindelse med lanceringen af Coloplasts nye 5-årige strategi, Impact4, offentliggør virksomheden en ny finansiel ambition med en organisk omsætningsvækst på 7-8 % (5-årige CAGR) frem til regnskabsåret 2029/30, en vækst i absolut EBIT* på niveau med eller over omsætningsvæksten i perioden og et afkast af investeret kapital (ROIC) på mere end 20 % i regnskabsåret 2029/30. På sin Capital Markets Day den 2. september 2025 vil Coloplast præsentere en ny 5-årig strategi, Impact4. I fo...

September 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch